Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy

M Korenkov1, J Liebaert1, S Yousefian1,2,3,4

  • 1Department of Hematology, Oncology and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.

Blood Cancer Journal
|October 20, 2025
PubMed
Summary

Ciltacabtagene-autoleucel CAR-T therapy can cause chronic inflammatory demyelinating polyneuropathy (CIDP). This severe complication may stem from bystander T-cells, suggesting T-cell-depleting therapy could improve outcomes.